Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Adenocarcinoma × sintilimab × Clear all

Phase

Status

Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1 Osteosarcoma 1 Histiocytoma, Malignant Fibrous 1 Hemangiosarcoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Advanced or Metastatic Solid Tumors 1 Adenocarcinoma of Lung 1 Adenocarcinoma 1

Interventions

Gemcitabine 6 pembrolizumab 5 Carboplatin 5 Capecitabine 5 Pemetrexed 3 Oxaliplatin 3 Irinotecan 3 osimertinib 2 Sunitinib 2 Radiotherapy 2 Paclitaxel 2 Fluorouracil 2 130-nm albumin-bound paclitaxel 2 trifluridine tipiracil drug combination 1 tislelizumab 1 tegafur-gimeracil-oteracil 1 technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1 sintilimab 1 seribantumab 1 selinexor 1 rubitecan 1 regorafenib 1 pralsetinib 1 olaparib 1 niraparib 1 linifanib 1 ixabepilone 1 ganitumab 1 eribulin 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05161572 2025-06-18

NeoRacing

Fudan University

Phase 2 Terminated

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡